TW200500085A - Sustained-release pharmaceutical composition for lung administration - Google Patents

Sustained-release pharmaceutical composition for lung administration

Info

Publication number
TW200500085A
TW200500085A TW093104753A TW93104753A TW200500085A TW 200500085 A TW200500085 A TW 200500085A TW 093104753 A TW093104753 A TW 093104753A TW 93104753 A TW93104753 A TW 93104753A TW 200500085 A TW200500085 A TW 200500085A
Authority
TW
Taiwan
Prior art keywords
sustained
pharmaceutical composition
release pharmaceutical
lung administration
active substance
Prior art date
Application number
TW093104753A
Other languages
English (en)
Chinese (zh)
Other versions
TWI332403B (https=
Inventor
Akira Yamamoto
Keigo Yamada
Original Assignee
Otsuka Pharma Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Otsuka Pharma Co Ltd filed Critical Otsuka Pharma Co Ltd
Publication of TW200500085A publication Critical patent/TW200500085A/zh
Application granted granted Critical
Publication of TWI332403B publication Critical patent/TWI332403B/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/731—Carrageenans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Otolaryngology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Inorganic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
TW093104753A 2003-02-26 2004-02-25 Sustained-release pharmaceutical composition for lung administration TW200500085A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2003049019 2003-02-26

Publications (2)

Publication Number Publication Date
TW200500085A true TW200500085A (en) 2005-01-01
TWI332403B TWI332403B (https=) 2010-11-01

Family

ID=32923305

Family Applications (1)

Application Number Title Priority Date Filing Date
TW093104753A TW200500085A (en) 2003-02-26 2004-02-25 Sustained-release pharmaceutical composition for lung administration

Country Status (9)

Country Link
US (1) US20060078504A1 (https=)
EP (1) EP1600170A4 (https=)
JP (1) JPWO2004075920A1 (https=)
KR (1) KR20050105490A (https=)
CN (1) CN1744917B (https=)
CA (1) CA2512434C (https=)
MY (1) MY142361A (https=)
TW (1) TW200500085A (https=)
WO (1) WO2004075920A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130150810A1 (en) * 2002-04-30 2013-06-13 The Population Council, Inc. Intravaginal ring for the delivery of unique combinations of antimicrobial compositions
US20080131454A1 (en) * 2006-12-05 2008-06-05 Marinomed Biotechnologie Gmbh Methods and Compositions for the Treatment of Rhinovirus Infections with Carrageenan
PL2178533T3 (pl) * 2007-08-24 2013-08-30 Marinomed Biotechnologie Gmbh Kompozycja przeciwwirusowa zawierająca siarczanowany polisacharyd: jota-karagen
CA2726221C (en) * 2008-07-01 2017-03-28 Marinomed Biotechnologie Gmbh Antiallergic marine biopolymers
EP2233130A1 (en) * 2009-03-23 2010-09-29 Genepharm (Europe) Trading Limited A sustained release oral composition of an antipsychotic agent
CN114191418B (zh) * 2021-12-21 2023-06-09 丽珠医药集团股份有限公司 噻托溴铵双层微球及其制备方法和噻托溴铵缓释吸入剂

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5192528A (en) * 1985-05-22 1993-03-09 Liposome Technology, Inc. Corticosteroid inhalation treatment method
US5200195A (en) * 1991-12-06 1993-04-06 Alza Corporation Process for improving dosage form delivery kinetics
CA2115444C (en) * 1992-06-12 2000-10-03 Yuji Makino Preparation for intratracheobronchial administration
US5612053A (en) * 1995-04-07 1997-03-18 Edward Mendell Co., Inc. Controlled release insufflation carrier for medicaments
US6126919A (en) * 1997-02-07 2000-10-03 3M Innovative Properties Company Biocompatible compounds for pharmaceutical drug delivery systems
JP2000070327A (ja) * 1998-09-01 2000-03-07 Kao Corp 鼻腔内洗浄具
US6579968B1 (en) * 1999-06-29 2003-06-17 Palatin Technologies, Inc. Compositions and methods for treatment of sexual dysfunction
US6461639B2 (en) * 2000-05-01 2002-10-08 Aeropharm Technology, Inc. Core formulation
NL1015288C2 (nl) * 2000-05-24 2001-12-14 Peter Ferdinand Elbers Preparaat voor het stabiliseren van de beschermlaag op het epitheel van het hoornvlies of de longblaasjes.
US6989156B2 (en) * 2001-04-23 2006-01-24 Nucryst Pharmaceuticals Corp. Therapeutic treatments using the direct application of antimicrobial metal compositions
US6475468B2 (en) * 2001-02-15 2002-11-05 Aeropharm Technology Incorporated Modulated release particles for aerosol delivery
US6749845B2 (en) * 2001-02-15 2004-06-15 Aeropharm Technology, Inc. Modulated release particles for lung delivery
US6551578B2 (en) * 2001-02-15 2003-04-22 Aeropharm Technology Incorporated Modulated release particles for aerosol delivery
JP2002255852A (ja) * 2001-03-01 2002-09-11 Toa Eiyo Ltd 口内炎用スプレー製剤
JP2003040766A (ja) * 2001-07-26 2003-02-13 Kao Corp 鼻腔内洗浄具

Also Published As

Publication number Publication date
EP1600170A4 (en) 2010-12-29
CN1744917B (zh) 2010-05-05
TWI332403B (https=) 2010-11-01
MY142361A (en) 2010-11-30
HK1083768A1 (zh) 2006-07-14
JPWO2004075920A1 (ja) 2006-06-01
CA2512434C (en) 2012-01-03
EP1600170A1 (en) 2005-11-30
KR20050105490A (ko) 2005-11-04
US20060078504A1 (en) 2006-04-13
CN1744917A (zh) 2006-03-08
CA2512434A1 (en) 2004-09-10
WO2004075920A1 (ja) 2004-09-10

Similar Documents

Publication Publication Date Title
AP1760A (en) Platinum derivative pharmaceutical formulations.
SE0102276D0 (sv) Device and method for the administration of a medicament
EP1477119A4 (en) METHOD FOR THE ADMINISTRATION OF MEDICINAL PRODUCTS
EP1708685A4 (en) GALENIC FORMS OF EFFERVESCENT ORAL OPIATES AND METHODS OF ADMINISTERING OPIATES
PL374443A1 (en) Novel pyrimidineamide derivatives and the use thereof
TW200738228A (en) Neramexane modified release matrix tablet
MX2007015480A (es) Formulaciones de dosificacion solida de medicamentos narcoticos que tienen adsorcion bucal mejorada.
DE60336225D1 (de) Neue pharmazeutische zusammenstezungen, flibanserin polymorph a enthaltend
GB2446341A (en) Method and system for transdermal drug delivery
GR20010100377A (el) Φαρμακευτικη συνθεση περιεχουσα σιταλοπραμη
EA200700158A1 (ru) Лекарственные формы с ядром таблетки, покрытым энтеросолюбильной оболочкой
TW200500085A (en) Sustained-release pharmaceutical composition for lung administration
SI1596841T1 (sl) Terapevtski sistem amoksicilina in klavulanske kisline
TW200503785A (en) Dosage form containing (S)-pantoprazole as active ingredient
TW200517127A (en) Novel composition
UA90504C2 (ru) Лекарственное средство для лечения заболеваний дыхательных путей
TW200509984A (en) Injectable dosage form of flupirtine
IL179177A (en) A pharmaceutical product including acyclovir and delivery compound, dosage unit, use of acyclovir in the preparation of the pharmaceutical product, use of the pharmaceutical product in the preparation of a drug and a method for the preparation of the pharmaceutical product
ATE256134T1 (de) Sulfatierte phosphatidylinositole, ihre herstellung und verwendung
SG146631A1 (en) Use of oxcarbazepine for the treatment of diabetic neuropathic pain and the improvement of sleep
CA2532714A1 (en) Oral sustained-release tablet comprising 4-(2-methyl-1-imidazolyl)-2,2-diphenylbutylamide
TW200633722A (en) Complexes made using low solubility drugs
WO2005049024A3 (de) Feste pharmazeutische zubereitungsform
UA88284C2 (ru) Твердая лекарственная форма, которая содержит действующее вещество из группы ингибиторов обратного захвата моноаминовых нейротрансмиттеров с 2,3-двухзамещенным тропановым скелетом, способ ее получения и применения
TW200515912A (en) Use of oxcarbazepine for the treatment of diabetic neuropathic pain and the improvement of sleep

Legal Events

Date Code Title Description
MM4A Annulment or lapse of patent due to non-payment of fees